BioXcel Therapeutics (BTAI) AGM 2025 summary

Opening remarks and agenda

• Meeting commenced at 9:00 A.M. Eastern Time with introductions of key executives and an overview of the agenda and voting procedures.

• Stockholders were informed about the rules of conduct, voting eligibility, and the process for submitting questions.

• Confirmation of quorum and appointment of Inspector of Election were announced.

Board and executive committee updates

• Three Class I directors—June Bray, Sandeep Laumas, and David Mack—were nominated for election to serve until the 2028 annual meeting.

Shareholder proposals

• Five proposals were presented: election of directors, ratification of Ernst & Young LLP as auditor, advisory approval of executive compensation, approval of a potential reverse stock split, and approval to adjourn the meeting if needed to solicit more proxies.

• The reverse stock split proposal was submitted as a precaution to maintain Nasdaq compliance, though the company is currently compliant.